Author: Extroverting

Read More

Psyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply deal

Psyence Biomedical (NASDAQ: PBM) invested an additional $500,000 in PsyLabs, deepening its relationship with the psychedelic ingredients producer while securing exclusive access to pharmaceutical-grade ibogaine. The cash infusion builds on Psyence’s initial partnership from September 2024, when it acquired an 11.13% equity stake in PsyLabs and locked down exclusive rights …